Radiation therapy for early stage (T1-T2) XXXX of true vocal cords: outcomes and patterns of failure.

@entity1 @entity135 @entity7841 @entity66 @entity5 @entity957 @entity189
@entity189 of @entity135 is a rare high-grade malignancy that may cause diagnostic and therapeutic controversies. A characteristic of this entity consistently reported but not entirely validated is its relative radioresistance and the general belief is that surgery is the treatment of choice. The objective of this retrospective study was to determine if @entity1 treated with radiation for early glottic @entity189 had worse outcomes than those achieved with @entity7841 for the more @entity957 . Twenty-eight cases of early stage (T1-T2) sarcomatoid @entity189 treated with definitive doses of megavoltage @entity7841 between 1969 and 1995 at The University of Texas M. D. Anderson Cancer Center form the cohort for this analysis. All pathologic material was reviewed to confirm the diagnosis. All @entity5 manifested spindle cell features with marked cytomorphologic abnormalities characteristic of this entity. Sixteen @entity5 (57%) had the more typical polypoid gross morphology of @entity189 . Twenty-one @entity1 (75%) were staged T1 and seven @entity1 (25%) had stage T2 disease. All @entity1 were treated with small laryngeal fields, median size 20 cm2, and to a median dose of 65 Gy. Follow-up ranged from 1.5 to 24 years (median, 10 years). Four @entity1 (14%) had @entity66 recurrence, and all had salvage total laryngectomies and remained free of @entity66 . The 5-year actuarial local control rates for @entity1 with T1 and T2 lesions were 94% and 54%, respectively. Only one @entity1 developed regional and distant disease. The 10-year actuarial disease-specific and overall survival rates were 92% and 63%, respectively. @entity1 with early stage @entity189 of the glottis treated with radiation had similar control rates to irradiated @entity1 with similar @entity66 with the more @entity957 . The authors contend that the histologic diagnosis of @entity189 by itself should not influence the decision to treat a @entity1 with early stage @entity66 with @entity7841 .
